Aevice Health Pte. Ltd. - Pioneer in AI-Powered Wearable Respiratory Monitoring

Company Profile (Updated April 2026)

Aevice Health Pte. Ltd. is a Singapore-based medical technology company pioneering AI-powered wearAble respiratory monitoring solutions. Founded in 2016 as a spin-off from Nanyang Technological University (NTU) by Adrian Ang (CEO) and Professor Ser Wee (Chief Scientist), the company has developed the AeviceMD Monitoring System—the world's smallest wearable stethoscope designed for continuous, remote monitoring of chronic respiratory diseases.

The company's flagship device, AeviceMD, represents a breakthrough in respiratory care, enabling patients with asthma, COPD, and other chronic lung conditions to monitor their health from home while providing clinicians with real-time, objective data for proactive intervention. In late 2024, Aevice Health secured $7 million in Seed+ funding led by Coronet Ventures (the venture unit of Cedars-Sinai Intellectual Property), positioning the company for accelerated global expansion into the US, Japan, and Australian markets.

Corporate History & Evolution

Founded: 2016 by Adrian Ang and Professor Ser Wee at Nanyang Technological University, Singapore
   Key Milestones:

- 2016: Company founded as NTU spin-off; began development of wearable respiratory monitoring technology

- 2019: CEO Adrian Ang recognized as Gen.T honoree for innovation leadership

- 2020: Launched first wearable device, AireSone Junior, for pediatric asthma monitoring

- 2021: Raised S$2.8 million ($2.1 million USD) in pre-Series A funding from Toho Holdings, Pureland Group Venture, Silicon Solutions Partners, AIP Ventures, and SEEDS Capital (Enterprise Singapore); entered strategic partnership with Toho Holdings for Japan market expansion

- 2022: Participated in Cedars-Sinai Accelerator Class 8 (USA) for US market entry preparation

- 2023: March—received Singapore HSA approval (first-in-market for wearable stethoscope); July—received first US FDA 510(k) clearance for adult use; January—awarded CES 2023 Best of Innovation Award in Digital Health category

- 2024: Closed $7 million Seed+ funding round led by Coronet Ventures (Cedars-Sinai) with participation from East Ventures; expanded clinical deployments in US hospitals and Singapore

- 2025: May—received FDA 510(k) clearance for pediatric use (ages 3+); June—secured Japan Patent Office patent grant for AeviceMD technology; December—received Australia TGA approval for pediatric wearable stethoscope (first in Australia); participated in SusHi Tech Tokyo (May) confirming Tokyo investor participation

- 2026: January—secured Singapore IP Office patent grant for AeviceMD technology

Company Type: Private Limited Company
   CEO & Co-Founder: Adrian Ang
   Chief Scientist & Co-Founder: Professor Ser Wee (NTU)
   Headquarters: Singapore
   Total Funding Raised: ~$9.1 million USD (across pre-Series A and Seed+ rounds)
   Website: www.aevicehealth.com

Revolutionary Product Portfolio

AeviceMD Monitoring System (Flagship)

The AeviceMD is a smart wearable stethoscope designed for continuous, remote respiratory monitoring. Worn on the patient's chest, the device combines proprietary AI algorithms with advanced acoustic sensors to detect abnormal breath sounds (including wheezing), monitor vital signs (heart rate, respiratory rate), and enable early detection of respiratory exacerbations.

Key Features:

- Continuous Monitoring: 24/7 remote monitoring of lung sounds and vital signs

- AI-Powered Wheeze Detection: Clinically validated algorithms with 92% accuracy in pediatric trials

- Real-Time Alerts: Automated detection of respiratory abnormalities for early intervention

- Digital Auscultation: Remote lung sound sharing with healthcare providers via mobile/web apps

- Patient-Friendly Design: Lightweight, comfortable, and suitable for ages 3+ (pediatric clearance)

Clinical Validation: Completed trials at Singapore's National University Hospital demonstrating superior wheeze detection compared to standard clinical stethoscope assessment.

AireSone Junior (Historical Product)

Launched in 2020, AireSone Junior was the company's first wearable device specifically designed for pediatric asthma management, recording and analyzing asthma symptoms in children to enable better home-based care.

Technological Innovation & Competitive Advantage

Internet-of-Medical-Things (IoMT) Platform: AeviceMD integrates hardware (wearable sensor), software (AI algorithms), and cloud infrastructure to create a comprehensive remote patient monitoring ecosystem.

AI-Powered Biomarker Analysis: The platform continuously analyzes respiratory biomarkers to predict exacerbations before they become critical, enabling proactive care similar to continuous glucose monitoring for diabetes.

Strategic AI Partnership: Aevice Health collaborates with Jiva.ai to integrate advanced AI capabilities for predictive analysis and personalized respiratory care.

Patent Portfolio: Secured patent protection in Japan (JPO, June 2025) and Singapore (IPOS, January 2026) covering AeviceMD's proprietary continuous respiratory monitoring system, strengthening global IP position.

Regulatory Achievements & Market Access

Multi-Market Regulatory Clearances:

- United States: FDA 510(k) clearance for adult use (July 2023); FDA 510(k) clearance for pediatric use ages 3+ (May 2025)—Class II medical device

- Singapore: Health Sciences Authority (HSA) first-in-market approval (March 2023)—first wearable stethoscope approved in Singapore; Singapore IP Office patent grant (January 2026)

- Australia: Therapeutic Goods Administration (TGA) approval (December 2025)—first pediatric wearable stethoscope approved in Australia, expedited under Comparable Overseas Regulator pathway recognizing Singapore HSA clearance; officially entered Australian market with pilot deployments (December 2025)

- Japan: Patent granted by Japan Patent Office (June 2025); strategic partnership with Toho Holdings for market entry; confirmed participation of Tokyo investors (A&D Company and others) following SusHi Tech Tokyo 2025 participation

Clinical Impact & Healthcare Value Proposition

Addressing Respiratory Disease Burden: Asthma and COPD affect over 545 million people globally, contributing to more than $130 billion annually in direct and indirect healthcare costs in the US alone. In Singapore, asthma affects 5% of adults and 20% of children, while COPD ranks among the top 10 causes of death.

Hospital-at-Home & Chronic Care Management: AeviceMD enables:

- Early Intervention: Detection of respiratory deterioration before emergency department visits

- Readmission Reduction: Continuous post-discharge monitoring to prevent costly hospital readmissions

- Care Continuum Extension: Bridging gaps between clinic visits with continuous remote monitoring

- Patient Empowerment: Enabling self-management of chronic respiratory conditions from home

Clinical Evidence: Achieved 92% wheeze detection accuracy in pediatric cohort studies at National University Hospital, Singapore.

Strategic Partnerships & Ecosystem

Japan Market Entry: Strategic partnership with Toho Holdings (Tokyo-listed pharmaceutical and medical equipment wholesaler operating 700+ pharmacies) to develop and market AeviceMD in Japan, addressing the country's significant respiratory disease burden; confirmed Tokyo investor participation including A&D Company.

US Market Development: Collaboration with Cedars-Sinai Medical Center through the Cedars-Sinai Accelerator, including pilot program development and clinical validation support. Coronet Ventures (Cedars-Sinai's venture arm) led the $7M Seed+ round.

Regional Expansion: Partnership with The Health Bank Global for Middle East, North Africa, and South Asia market access.

AI Development: Collaboration with Jiva.ai for advanced predictive analytics and personalized care algorithms.

Global Market Expansion Strategy (2026)

United States: Accelerating commercialization following pediatric FDA clearance; engaging hospitals, respiratory specialists, and home care programs for enterprise deployments.

Japan: Leveraging Toho Holdings partnership, JPO patent protection, and Tokyo investor network to enter the world's third-largest healthcare market, with focus on aging population and chronic respiratory disease management.

Australia: First-mover advantage as the only TGA-approved pediatric wearable stethoscope; actively establishing pilot deployments with hospitals and respiratory specialists for outpatient asthma management and remote patient monitoring pathways following December 2025 market entry.

Additional Markets: Active pursuit of regulatory approvals across Asia-Pacific and European markets to address the global respiratory health crisis.

Investment & Financial Overview

Funding History:

- Pre-Series A (2021): S$2.8 million ($2.1M USD) from Toho Holdings, Pureland Group Venture, Silicon Solutions Partners, AIP Ventures, SEEDS Capital (Enterprise Singapore)

- Seed+ Round (2024): $7 million USD led by Coronet Ventures (Cedars-Sinai), with participation from East Ventures

Total Raised: Approximately $9.1 million USD
   Company Valuation: Privately held (valuation not disclosed)
   Revenue Model: B2B and B2B2C—device sales, recurring software subscriptions, and remote monitoring services

2026 Outlook & Strategic Vision

Intellectual Property Expansion: Following Singapore patent grant (January 2026), continued pursuit of global patent portfolio expansion to protect core AI and wearable stethoscope technologies.

Regulatory Expansion: Pursuing additional regulatory clearances in European and Asian markets to expand global footprint beyond current US, Singapore, Australia, and Japan presence.

Product Pipeline: Development of next-generation AI algorithms for predictive respiratory health analytics, expanded pediatric applications, and integration with broader telehealth platforms.

Clinical Validation: Ongoing large-scale clinical studies to demonstrate long-term outcomes, cost-effectiveness, and reduction in emergency department visits and hospitalizations.

Strategic Partnerships: Expansion of partnerships with pharmaceutical companies, insurers, and health systems to embed AeviceMD into comprehensive chronic respiratory disease management programs.

Mission: To become the "continuous glucose monitor for respiratory health"—providing patient-centric, affordable, and accessible solutions that empower patients to achieve healthy recovery from the comfort of their homes while enabling healthcare providers to deliver proactive, personalized care at scale.

Contact Information

Singapore Headquarters

Company: Aevice Health Pte. Ltd.
   Website: www.aevicehealth.com
   Email: info@aevicehealth.com

Key Personnel

CEO & Co-Founder: Adrian Ang
   Chief Scientist & Co-Founder: Professor Ser Wee (NTU)
   CTO: Dr. Rex Tan

Keywords: Aevice Health,爱维斯健康,AeviceMD,wearable stethoscope,AI respiratory monitoring,remote patient monitoring,Singapore MedTech,Adrian Ang,Ser Wee,NTU spin-off,asthma monitoring,COPD monitoring,wheeze detection,Coronet Ventures,Cedars-Sinai,East Ventures,Toho Holdings,$7 million funding,Seed+ round,FDA 510k pediatric,HSA approval,TGA approval,Japan patent,Singapore patent 2026,CES 2023 Best of Innovation,respiratory health,telehealth,hospital at home,SusHi Tech Tokyo,A&D Company,Jiva.ai